Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Hematology Department, CHU Hotel-Dieu, Nantes, France patrice.chevallier@chu-nantes.fr.
Patrice
P
Chevallier
Hematology Department, CHU, Caen, France.
Sylvain
S
Chantepie
Hematology Department, CHU, Toulouse, France.
Francoise
F
Huguet
Hematology Department, Hôpital Saint-Louis, Paris, France.
Emmanuel
E
Raffoux
Hematology Department, CHU, Lyon, France.
Xavier
X
Thomas
Hematology Department, CHU, Bordeaux, France.
Thibaut
T
Leguay
Hematology Department, CHU, Rennes, France.
Tony
T
Marchand
Hematology Department, Hopital Saint-Antoine, Paris, France.
Francoise
F
Isnard
Hematology Department, Institut Paoli-Calmette, Marseille, France.
Aude
A
Charbonnier
Hematology Department, CHU Henri Mondor, Créteil, France.
Sébastien
S
Maury
Hematology Department, CHU, Poitiers, France.
Maria-Pilar
MP
Gallego-Hernanz
Hematology/Biology, CHU Hotel-Dieu, Nantes, France.
Nelly
N
Robillard
Hematology Department, CHU Hotel-Dieu, Nantes, France.
Thierry
T
Guillaume
Hematology Department, CHU Hotel-Dieu, Nantes, France.
Pierre
P
Peterlin
Hematology Department, CHU Hotel-Dieu, Nantes, France.
Alice
A
Garnier
Hematology Department, CHU Hotel-Dieu, Nantes, France.
Fanny
F
Rialland
Hematology Department, CHU Hotel-Dieu, Nantes, France.
Claire
C
Le Houerou
Immunomedics, Inc., Morris Plains, NJ, USA.
David M
DM
Goldenberg
Immunomedics, Inc., Morris Plains, NJ, USA.
William A
WA
Wegener
Hematology/Biology, CHU Hotel-Dieu, Nantes, France.
Marie-C
MC
Béné
Hematology Department, Hôpital Saint-Louis, Paris, France.
Hervé
H
Dombret
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D012008:Recurrence; D019233:Retreatment; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000378:metabolism*; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; C497867:CD22 protein, human; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide